Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).
Saved in:
| Title: | Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). |
|---|---|
| Authors: | Santoni M; Oncology Unit, Macerata Hospital, Macerata, Italy., Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. giandomenico.roviello@unifi.it., Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Fiala O; Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic., Seront E; Department of Medical Oncology, Cliniques Universitaires Saint-Luc 1200, Brussels, Belgium., Molina-Cerrillo J; Hospital Ramón y Cajal, Madrid, Spain., Pichler R; Department of Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria., Myint ZW; Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA., Kucharz J; Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland., Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Büttner T; Department of Urology, University Hospital Bonn (UKB), 53127, Bonn, Germany., Pichler M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Augenbruggerplatz 15, 8010, Graz, Austria., Basso U; Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Kopecky J; Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czechia., Bourlon MT; Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Cerbone L; Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy., Buchler T; Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital Prague, Prague, Czech Republic., Pinto A; Medical Oncology Department, La Paz University Hospital, Madrid, Spain., de Liaño AG; Medical Oncology Department, CHU Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain., Gianni C; Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Zgura A; Department of Obstetrics-Radiotherapy, Alexandru Trestioreanu Institute of Oncology, 'Carol Davila' University of Medicine and Pharmacy, Prof. Dr, Bucharest, Romania., Rescigno P; Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, UK., Ansari J; Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates., Caffo O; Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy., Küronya Z; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary., Vitale MG; Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy., Bhuva D; Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India., Catalano M; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy., Vau N; Urologic Oncology, Champalimaud Clinical Center, 1400-038, Lisbon, Portugal., Kopp RM; Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., Buti S; Medical Oncology Unit, University Hospital of Parma, 43126, Parma, Italy., Bamias A; 2nd Propaedeutic Department of Internal Medicine, School of Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Athens, Greece., Porta C; Interdisciplinary Department of Medicina, University of Bari 'Aldo Moro' and Division of Medical Oncology, A.O.U. Consorziale Policlinico Di Bari, Bari, Italy., Sunela K; Finnish Medicines Agency Fimea, Tampere, Finland., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni, 15, Bologna, Italy. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 May 27; Vol. 74 (7), pp. 225. Date of Electronic Publication: 2025 May 27. |
| Publication Type: | Journal Article; Comparative Study; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40423789 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Santoni+M%22">Santoni M</searchLink>; Oncology Unit, Macerata Hospital, Macerata, Italy.<br /><searchLink fieldCode="AU" term="%22Roviello+G%22">Roviello G</searchLink>; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. giandomenico.roviello@unifi.it.<br /><searchLink fieldCode="AU" term="%22Grande+E%22">Grande E</searchLink>; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22De+Giorgi+U%22">De Giorgi U</searchLink>; Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.<br /><searchLink fieldCode="AU" term="%22Fiala+O%22">Fiala O</searchLink>; Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Seront+E%22">Seront E</searchLink>; Department of Medical Oncology, Cliniques Universitaires Saint-Luc 1200, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Molina-Cerrillo+J%22">Molina-Cerrillo J</searchLink>; Hospital Ramón y Cajal, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Pichler+R%22">Pichler R</searchLink>; Department of Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.<br /><searchLink fieldCode="AU" term="%22Myint+ZW%22">Myint ZW</searchLink>; Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA.<br /><searchLink fieldCode="AU" term="%22Kucharz+J%22">Kucharz J</searchLink>; Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Kanesvaran+R%22">Kanesvaran R</searchLink>; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Büttner+T%22">Büttner T</searchLink>; Department of Urology, University Hospital Bonn (UKB), 53127, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Pichler+M%22">Pichler M</searchLink>; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Augenbruggerplatz 15, 8010, Graz, Austria.<br /><searchLink fieldCode="AU" term="%22Basso+U%22">Basso U</searchLink>; Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.<br /><searchLink fieldCode="AU" term="%22Kopecky+J%22">Kopecky J</searchLink>; Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czechia.<br /><searchLink fieldCode="AU" term="%22Bourlon+MT%22">Bourlon MT</searchLink>; Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.<br /><searchLink fieldCode="AU" term="%22Cerbone+L%22">Cerbone L</searchLink>; Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Buchler+T%22">Buchler T</searchLink>; Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital Prague, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Pinto+A%22">Pinto A</searchLink>; Medical Oncology Department, La Paz University Hospital, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22de+Liaño+AG%22">de Liaño AG</searchLink>; Medical Oncology Department, CHU Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain.<br /><searchLink fieldCode="AU" term="%22Gianni+C%22">Gianni C</searchLink>; Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.<br /><searchLink fieldCode="AU" term="%22Zgura+A%22">Zgura A</searchLink>; Department of Obstetrics-Radiotherapy, Alexandru Trestioreanu Institute of Oncology, 'Carol Davila' University of Medicine and Pharmacy, Prof. Dr, Bucharest, Romania.<br /><searchLink fieldCode="AU" term="%22Rescigno+P%22">Rescigno P</searchLink>; Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, UK.<br /><searchLink fieldCode="AU" term="%22Ansari+J%22">Ansari J</searchLink>; Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates.<br /><searchLink fieldCode="AU" term="%22Caffo+O%22">Caffo O</searchLink>; Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy.<br /><searchLink fieldCode="AU" term="%22Küronya+Z%22">Küronya Z</searchLink>; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Vitale+MG%22">Vitale MG</searchLink>; Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.<br /><searchLink fieldCode="AU" term="%22Bhuva+D%22">Bhuva D</searchLink>; Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India.<br /><searchLink fieldCode="AU" term="%22Catalano+M%22">Catalano M</searchLink>; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy.<br /><searchLink fieldCode="AU" term="%22Vau+N%22">Vau N</searchLink>; Urologic Oncology, Champalimaud Clinical Center, 1400-038, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Kopp+RM%22">Kopp RM</searchLink>; Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.<br /><searchLink fieldCode="AU" term="%22Buti+S%22">Buti S</searchLink>; Medical Oncology Unit, University Hospital of Parma, 43126, Parma, Italy.<br /><searchLink fieldCode="AU" term="%22Bamias+A%22">Bamias A</searchLink>; 2nd Propaedeutic Department of Internal Medicine, School of Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Porta+C%22">Porta C</searchLink>; Interdisciplinary Department of Medicina, University of Bari 'Aldo Moro' and Division of Medical Oncology, A.O.U. Consorziale Policlinico Di Bari, Bari, Italy.<br /><searchLink fieldCode="AU" term="%22Sunela+K%22">Sunela K</searchLink>; Finnish Medicines Agency Fimea, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Massari+F%22">Massari F</searchLink>; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni, 15, Bologna, Italy. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2025 May 27; Vol. 74 (7), pp. 225. <i>Date of Electronic Publication: </i>2025 May 27. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Comparative Study; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40423789 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00262-025-04043-x Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 225 Titles: – TitleFull: Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Santoni M – PersonEntity: Name: NameFull: Roviello G – PersonEntity: Name: NameFull: Grande E – PersonEntity: Name: NameFull: De Giorgi U – PersonEntity: Name: NameFull: Fiala O – PersonEntity: Name: NameFull: Seront E – PersonEntity: Name: NameFull: Molina-Cerrillo J – PersonEntity: Name: NameFull: Pichler R – PersonEntity: Name: NameFull: Myint ZW – PersonEntity: Name: NameFull: Kucharz J – PersonEntity: Name: NameFull: Kanesvaran R – PersonEntity: Name: NameFull: Büttner T – PersonEntity: Name: NameFull: Pichler M – PersonEntity: Name: NameFull: Basso U – PersonEntity: Name: NameFull: Kopecky J – PersonEntity: Name: NameFull: Bourlon MT – PersonEntity: Name: NameFull: Cerbone L – PersonEntity: Name: NameFull: Buchler T – PersonEntity: Name: NameFull: Pinto A – PersonEntity: Name: NameFull: de Liaño AG – PersonEntity: Name: NameFull: Gianni C – PersonEntity: Name: NameFull: Zgura A – PersonEntity: Name: NameFull: Rescigno P – PersonEntity: Name: NameFull: Ansari J – PersonEntity: Name: NameFull: Caffo O – PersonEntity: Name: NameFull: Küronya Z – PersonEntity: Name: NameFull: Vitale MG – PersonEntity: Name: NameFull: Bhuva D – PersonEntity: Name: NameFull: Catalano M – PersonEntity: Name: NameFull: Vau N – PersonEntity: Name: NameFull: Kopp RM – PersonEntity: Name: NameFull: Buti S – PersonEntity: Name: NameFull: Bamias A – PersonEntity: Name: NameFull: Porta C – PersonEntity: Name: NameFull: Sunela K – PersonEntity: Name: NameFull: Massari F IsPartOfRelationships: – BibEntity: Dates: – D: 27 M: 05 Text: 2025 May 27 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1432-0851 Numbering: – Type: volume Value: 74 – Type: issue Value: 7 Titles: – TitleFull: Cancer immunology, immunotherapy : CII Type: main |
| ResultId | 1 |
